Ingersoll Rand (IR) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
15 Nov, 2026Financial profile and market performance
LTM Q3 2025 revenue was ~$7.5B, adjusted EBITDA ~$2.0B, adjusted EBITDA margin ~27%, and free cash flow ~$1.3B; free cash flow margin was ~20%.
Reported revenue was $7.5B, with a 27% EBITDA margin and 17% free cash flow margin; market capitalization was $34B.
Revenue grew at ~8% CAGR and adjusted diluted EPS at ~11% CAGR from 2022 through LTM Q3 2025.
Since the May 2017 IPO, share price appreciation was ~328%, outperforming the S&P 500 by ~13,500 bps; market-cap value creation was ~$30B through Jan. 9, 2026.
Total shareholder return exceeded 330% since 2017, with double-digit EPS CAGR despite industry headwinds; aftermarket consumables represent 37% of revenue.
Strategy and M&A
IRX improved EBITDA margins by 600+ bps over five years; IRX and demand generation are expected to support above-market growth.
Completed 76 acquisitions since March 2020, including 16 bolt-ons in 2025 at an average pre-synergy purchase multiple of ~9x EBITDA.
M&A flywheel supports annual bolt-ons, with multiples reduced post-integration; four life science deals in the past year averaged 10x EBITDA and target mid-teens ROIC within three years.
Active pipeline includes ~100 companies, with 10 in active discussions at any time; deals are selected for strategic fit, unique capabilities, and value creation.
Life science additions include Leadfluid, Dave Barry Plastics, and Sheridan Mold & Engineering in 2025, and scinomix in January 2026; ILC Dover provided a platform for bolt-ons.
Life science platform and growth
Life Science Technologies covers flow control, biopharma and pharma, and medical device solutions, including pumps, containment, material handling, and contract device manufacturing.
Estimated life sciences revenue mix rose from 4% in 2020 to 18% in 2024; brands include ILC Dover and Flexan.
85% of life science revenue comes from recurring consumables; highly specified products are integrated into customer applications.
Positioned in weight-loss therapies, oncology, minimally invasive procedures, diagnostics, and antibody drug conjugates, which are expected to grow at a mid-teens rate.
Global footprint spans North America and Europe, with growing presence in Asia; solutions cover small-molecule API workflows from containment and transfer to temperature control, drying, and packaging.
Latest events from Ingersoll Rand
- Orders rose 21%; FY2026 revenue and adjusted EPS guidance increased.IR
Q3 2026 - Growth accelerates with strong orders, margin recovery, and disciplined M&A fueling future upside.IR
Morgan Stanley's 14th Annual Laguna Conference - Order momentum and margin recovery are accelerating, driven by volume growth and recurring revenue.IR
Jefferies Global Industrials Conference 2026 - Order momentum and recurring revenue growth accelerate, with margins set to improve into 2027.IR
Deutsche Bank’s Chicago Industrials Summit - Q2 2026 delivered strong growth, higher guidance, and robust liquidity and M&A activity.IR
Q2 2026 - Global expansion, recurring revenue, and innovation drive growth amid prudent guidance.IR
Citi's Global Industrial Tech & Mobility Conference 2026 - Q1 organic order growth, robust backlog, and recurring revenue expansion drive margin gains.IR
18th Annual Global Transportation & Industrials Conference - Q3 2025 saw 5.1% revenue growth, margin resilience, and strong cash flow despite tariff headwinds.IR
Q3 2025 - Record Q1 orders, robust cash flow, and expanded buyback highlight strong financial momentum.IR
Q1 2025